Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective resp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Zuazo, Miren, Arasanz, Hugo, Fernández‐Hinojal, Gonzalo, García‐Granda, Maria Jesus, Gato, María, Bocanegra, Ana, Martínez, Maite, Hernández, Berta, Teijeira, Lucía, Morilla, Idoia, Lecumberri, Maria Jose, Fernández de Lascoiti, Angela, Vera, Ruth, Kochan, Grazyna, Escors, David
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6609910/
https://ncbi.nlm.nih.gov/pubmed/31273938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910293
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados